Učitavanje...
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
With an estimated prevalence of 5.8 million in the USA and over 23 million people worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of guideline-directed medical therapies such as angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, angiotensin receptor...
Spremljeno u:
| Izdano u: | Vasc Health Risk Manag |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5634378/ https://ncbi.nlm.nih.gov/pubmed/29042791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S114784 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|